1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Coronavirus Update: Clover Begins Twin Track Trials With GSK And Dynavax

Plus: Are UK's New Takeover Laws Prompted By AstraZeneca Fears?

 
• By Scrip Team

Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.    

Sharma_Alok
UK business minister Alok Sharma: new laws would allow government to block a vaccines company takeover.

China’s Clover Biopharmaceuticals has dosed the first volunteers in its COVID-19 vaccine candidate Phase I trials, and is testing it in conjunction with two separate adjuvants, one from GlaxoSmithKline PLC and the other from Dynavax Technologies Corp.

The start of Clover’s first-in-human studies on 19 June brings the total of major vaccine candidates in clinical trials to nine, maintaining hopes that at least one will show

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

More from R&D

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.